Chronic exposure to a synthetic cannabinoid improves cognition and increases locomotor activity in Tg4-42 Alzheimer's disease mice.

ABSTRACT:

Background

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive decline and behavior impairments. Despite recent approvals of anti-amyloid antibodies, there remains a need for disease modifying and easily accessible therapies. Emerging evidence suggests that targeting the endocannabinoid system may hold promise for AD therapy as it plays a crucial role in different physiological processes, including learning, memory and anxiety, as well as inflammatory and immune responses.

Objective

In this study, we investigated the therapeutic potential of the synthetic cannabinoid WIN 55,212-2 on memory deficits in Tg4-42 transgenic mice.

Methods

Tg4-42 mice were assigned to two treatment groups to investigate the preventive effects of WIN 55,212-2 a

SUBMITTER: Ott FW 

PROVIDER: S-EPMC11869267 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature